Abstract
Adolescents and young adults occupy a unique place within the cancer community due to the challenges they face related to disease biology, access to care, and psychosocial and socioeconomic circumstances. Efforts to define specific needs and targets for intervention in these areas are under way and evolving. This review will discuss the current and future challenges in delivering quality care to this population.
Journal Section:
Editor's choice
References
1.
Bleyer A, O'Leary M, Barr R, Ries LAG (eds): Cancer Epidemiology in Older Adolescents and Young Adults 15-29 Years of Age, Including SEER Incidence and Survival: 1975-2000. NIH Publ No 06-5767. Bethesda, National Cancer Institute, 2006.
2.
Bleyer A, Budd T, Montello M: Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer 2006;107(suppl):1645-1655.
[PubMed]
3.
Surveillance, Epidemiology, and End Results (SEER) program: Seer*Stat database: incidence-SEER 13 Regs, public-use Nov 2004 sub for expanded races (1992-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission. www.seer.cancer.gov (accessed November 8, 2005).
4.
Adolescents and young adults with cancer. Bethesda, National Cancer Institute at the National Institutes of Health, 2013. http://www.cancer.gov/cancertopics/aya/reports (accessed July 31, 2013).
5.
Wood WA, Lee SJ: Malignant hematologic diseases in adolescents and young adults. Blood 2011;117:5803-5815.
[PubMed]
6.
Collins SR, Garber T, Doty M: Young, uninsured, and in debt: why young adults lack health insurance and how the affordable care act is helping. Findings from the Commonwealth Fund Health Insurance Tracking Survey of young adults, 2011. Commonwealth Fund 2012;14:1-24.
[PubMed]
7.
Pulte D, Gondos A, Brenner H: Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981-2005. Cancer 2009;115:4973-4979.
[PubMed]
8.
National Comprehensive Cancer Network: Adolescent and young adult (AYA) oncology (version 1.2012). http://www.nccn.org/professionals/physician_gls/pdf/aya.pdf (accessed May 25, 2013).
9.
Ramphal R, Meyer R, Schacter B, Rogers P, Pinkerton R: Active therapy and models of care for adolescents and young adults with cancer. Cancer 2011;117(suppl):2316-2322.
[PubMed]
10.
Bleyer A: Young adult oncology: the patients and their survival challenges. CA Cancer J Clin 2007;57:242-255.
[PubMed]
11.
Liu L, Krailo M, Reaman GH, Bernstein L; Surveillance, Epidemiology and End Results Childhood Cancer Linkage Group: Childhood cancer patients' access to cooperative group cancer programs: a population-based study. Cancer 2003;97:1339-1345.
[PubMed]
12.
Bleyer A, Montello M, Budd T: Young adults with leukemia in the United States: lack of clinical trial participation and mortality reduction during the last decade. JCO Meeting Abstracts July 2004, vol 22, No 14, suppl 6623. http://meeting.ascopubs.org/cgi/content/abstract/22/14_suppl/6623.
13.
Bleyer A, Budd T, Montello M: Older adolescents and young adults with cancer, and clinical trials: lack of participation and progress in North America; in Bleyer A, Barr R, Albritton K, Phillips M, Siegel S (eds): Cancer in Adolescents and Young Adults. New York, Springer, 2007, pp 71-81.
14.
Freyer DR, Felgenhauer J, Perentesis J; COG Adolescent and Young Adult Oncology Discipline Committee: Children's Oncology Group's 2013 blueprint for research: adolescent and young adult oncology. Pediatr Blood Cancer 2013;60:1055-1058.
[PubMed]
15.
Clinton-McHarg T, Paul C, Sanson-Fisher R, D'Este C, Williamson A: Determining research priorities for young people with haematological cancer: a value-weighting approach. Eur J Cancer 2010;46:3263-3270.
[PubMed]
16.
Effective Health Care Program: Helping you make better treatment choices: what is comparative effectiveness research. Rockville, Agency for Healthcare Research and Quality, US Department of Health and Human Services, 2013. http://www.effectivehealthcare.ahrq. gov/index.cfm/what-is-comparative-effectiveness-research1/ (accessed July 24, 2013).
17.
Edge SB, Zwelling LA, Hohn DC: The anticipated and unintended consequences of the Patient Protection and Affordable Care Act on cancer research. Cancer J 2010;16:606-613
[PubMed]
18.
Singal PK, Iliskovic N, Li T, Kumar D: Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997;11:931-936.
[PubMed]
19.
Sleijfer S: Bleomycin-induced pneumonitis. Chest 2001;120:617.
[PubMed]
20.
Mudie NY, Swerdlow AJ, Higgins CD, Smith P, Qiao Z, Hancock BW, Hoskin PJ, Linch DC: Risk of second malignancy after non-Hodgkin's lymphoma: a British cohort study. J Clin Oncol 2006;24:1568-1574.
[PubMed]
21.
Koontz MZ, Horning SJ, Balise R, Greenberg PL, Rosenberg SA, Hoppe RT, Advani RH: Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. J Clin Oncol 2013;31:592-598.
[PubMed]
22.
Pedersen-Bjergaard J, Andersen MK, Christiansen DH: Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000;95:3273-3279.
[PubMed]
23.
Chemaitilly W, Sklar CA: Endocrine complications in long-term survivors of childhood cancers. Endocr Relat Cancer 2010;17:R141-R159.
[PubMed]
24.
Chow E: Risk of thyroid dysfunction and subsequent thyroid cancer among survivors of acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Trial. Pediatr Blood Cancer 2009;53:432-437.
[PubMed]
25.
Brennan BM, Rahim A, Mackie EM, Eden OB, Shalet SM: Growth hormone status in adults treated for acute lymphoblastic leukaemia in childhood. Clin Endocrinol (Oxf) 1998;48:777-783.
[PubMed]
26.
Fox S: E-patients with a disability or chronic disease. Washington, Pew Research Center, October 8, 2007. http://www.pewinternet.org/ Reports/2007/EpatientsWith-a-Disability-or-Chronic-Disease.aspx (accessed July 31, 2013).
27.
Fox S, Jones S: The social life of health information. Washington, Pew Research Center, June 2009. http://www.pewinternet.org/Reports/2009/8-The-Social-Life-of (accessed July 31, 2013).
28.
Rainie L: Two-thirds of young adults and those with higher income are smartphone owners. Washington, Pew Research Center, September 11, 2012. http://www.pewinternet.org/Reports/2012/PIP_Smartphones_Sept12%209%2010%2012.pdf (accessed July 31, 2013).
29.
Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Beck LN, Brennan LV, Oktay K: American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-2931.
[PubMed]
30.
Tierney KD, Facione N, Padilla G, Blume K, Dodd M: Altered sexual health and quality of life in women prior to hematopoietic cell transplantation. Eur J Oncol Nurs 2007;11:298-308.
[PubMed]
31.
Goodwin T, Oosterhuis EB, Kiernan M, Hudson MM, Dahl GV: Attitudes and practices of pediatric oncology providers regarding fertility issues. Pediatr Blood Cancer 2007;4:80-85.
[PubMed]
32.
Levine J, Canada A, Stern CJ: Fertility preservation in adolescents and young adults with cancer. J Clin Oncol 2010;28:4831-4841.
[PubMed]
33.
Jadoul P, Kim SS; ISFP Practice Committee: Fertility considerations in young women with hematological malignancies. J Assist Reprod Genet 2012;29:479-487.
[PubMed]
34.
The Ethics Committee of the American Society for Reproductive Medicine: Fertility preservation and reproduction in cancer patients. Fertil Steril 2005;83:1622-1628.
[PubMed]
35.
Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Patridge AH, Quinn G, Wallace WH, Oktay K: Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2500-2510.
[PubMed]
36.
ISPF Practice Committee, Kim SS, Donnez J, Barri P, Pellicer A, Patrizio P, Rosenwaks Z, Nagy P, Falcone T, Andersen C, Hovatta O, Wallace H, Meirow D, Gook D, Kim SH, Tzeng C, Suzuki S, Ishizuka B, Dolmans M: Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J Assist Reprod Genet 2012;29:465-468.
[PubMed]
37.
Hodgson DC, Pintilie M, Gitterman L, Dewitt B, Buckley CA, Ahmed S, Smith K, Schwartz A, Tsang RW, Crump M, Wells W, Sun A, Gospodarowicz MK: Fertility among female Hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol 2007;25:11-15.
[PubMed]
38.
Sieniawski M, Reinecke T, Novoga L, Josting A, Pfisner B, Diehl V, Engert A: Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008;111:71-76.
[PubMed]
39.
Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, Wessels C, Wiehlpütz M, Rosenbrock J, Halbsguth T, Reiners KS, Schober T, Renno JH, von Wolff M, van der Ven K, Kuehr M, Fuchs M, Diehl V, Engert A, Borchmann P: Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 2013;31:231-239.
[PubMed]
40.
De Luyk N, Pozzato G, Ricci G, Tamaro P, Manno M, Tomei F, Trombetta C: Pre-treatment and posttreatment fertility in young male patients affected by Hodgkin and non-Hodgkin lymphoma. Arch Ital Urol Androl 2012;84:141-145.
[PubMed]
41.
Conchon M, Sanabani SS, Bendit I, Santos FM, Serpa M, Dorliac-Llacer PE: Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. J Hematol Oncol 2009;2:42.
[PubMed]
42.
Cole S, Kantarjian H, Ault P, Cortés JE: Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature. Clin Lymphoma Myeloma 2009;9:324-327.
[PubMed]
43.
Salooja N, Szydlo RM, Socie G, Rio B, Chatterjee R, Ljungman P, Van Lint MT, Powles R, Jackson G, Hinterberger-Fischer M, Kolb HJ, Apperly JF; Late Effects Working Party of the European Group for Blood and Marrow Transplantation: Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet 2001;358:271-276.
[PubMed]
44.
Sanders JE, Pritchard S, Mahoney P, Amos D, Buckner CD, Witherspoon RP, Deeg HJ, Doney KC, Sullivan KM, Appelbaum FR: Growth and development following marrow transplantation for leukemia. Blood 1986;68:1129-1135.
[PubMed]
45.
Jadoul P, Anckaert E, Dewandeleer A, Steffens M, Dolmans MM, Vermylen C, Smitz J, Donnez J, Maiter D: Clinical and biologic evaluation of ovarian function in women treated by bone marrow transplantation for various indications during childhood or adolescence. Fertil Steril 2011;96:126-133.
[PubMed]
46.
Sanders JE, Hawley J, Levy W, Gooley T, Buckner CD, Deeg HJ, Doney K, Storb R, Sullivan K, Witherspoon R, Appelbaum FR: Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996;87:3045-3052.
[PubMed]
47.
Carter A, Robison LL, Francisco L, Smith D, Grant M, Baker KS, Gurney JG, McGlave PB, Weisdorf DJ, Forman SJ, Bhatia S: Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the Bone Marrow Transplant Survivor Study. Bone Marrow Transplant 2006;37:1023-1029.
[PubMed]
48.
Koehler M, Koenigsmann M, Frommer J: Coping with illness and subjective theories of illness in adult patients with haematological malignancies: systematic review. Crit Rev Oncol Hematol 2009;69:237-257.
[PubMed]
49.
Mosher CE, Duhamel KN, Rini CM, Li Y, Isola L, Labay L, Rowley S, Papadopoulos E, Moskowitz C, Scigliano E, Grosskreutz C, Redd WH: Barriers to mental health service use among hematopoietic SCT survivors. Bone Marrow Transplant 2010;45:570-579.
[PubMed]
50.
Fry R: Young adults after the recession: fewer homes, fewer cars, less debt. Washington, Pew Research Center, February 21, 2013. http://www.pewinternet.org/files/2013/02/Financial_Milestones_of_Young_Adults_ FINAL_2-19.pdf (accessed July 31, 2013).
51.
Martin S, Ulrich C, Munsell M, Taylor S, Lange G, Bleyer A: Delays in cancer diagnosis in underinsured young adults and older adolescents. Oncologist 2007;12:816-824.
[PubMed]
52.
Schwartz K, Claxton G: The Patient Protection and Affordable Care Act: how will it affect private health insurance for cancer patients? Cancer J 2010;16:572-576.
[PubMed]
53.
Hutchins VA, Samuels MB, Lively AM: Analyzing the Affordable Care Act: essential health benefits and implications for oncology. J Oncol Pract 2013;9:73-77.
[PubMed]
54.
Bailes JS, Kamin DY, Foster SE: The Patient Protection and Affordable Care Act: exploring the potential impact on oncology practice. Cancer J 2010;16:588-592.
[PubMed]
55.
Albright HW, Moreno M, Feeley TW, Walters R, Samuels M, Pereira A, Burke TW: The implications of the 2010 Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act on cancer care delivery. Cancer 2011;117:1564-1574.
[PubMed]
56.
Bleyer WA: Potential favorable impact of the Affordable Care Act of 2010 on cancer in young adults in the United States. Cancer J 2010;16:563-571.
[PubMed]
57.
Sommers BD, Buchmueller T, Decker SL, Carey C, Kronick R: The Affordable Care Act has led to significant gains in health insurance and access to care for young adults. Health Aff (Millwood) 2013;32:165-174.
[PubMed]
58.
Cantor J, Monheit A, DeLia D, Lloyd K: Early impact of the Affordable Care Act on health insurance coverage of young adults. Health Serv Res 2012;47:1773-1789.
[PubMed]
59.
ClinicalTrials.gov. Bethesda, National Institutes of Health, 2013. http://www.clinicaltrials.gov (accessed July 31, 2013).
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.
